Immunology · 2015 · 110 citations · 30 references
Life SciencesImmunologyInfectious DiseasesImmunizationMucosal ImmunologyVaccinologyMucosal ImmunizationMucosal VaccinesVaccinationVector-based VaccinesViral VaccinesViral Vector VaccinesAdenoviral Vaccine VectorsAdenoviral VectorsAdenovirus VaccinesAdenovirus VectorsAntigen-specific Immune ResponseAntigen-specific T Cell ResponsesMiddle East Respiratory Syndrome CoronavirusVectored Vaccines
An ideal vaccine against mucosal pathogens such as Middle East respiratory syndrome coronavirus (MERS-CoV) should confer sustained, protective immunity at both systemic and mucosal levels. Here, we evaluated the in vivo systemic and mucosal antigen-specific immune responses induced by a single intramuscular or intragastric administration of recombinant adenoviral type 5 (Ad5) or type 41 (Ad41) -based vaccines expressing the MERS-CoV spike (S) protein. Intragastric administration of either Ad5-S or Ad41-S induced antigen-specific IgG and neutralizing antibody in serum; however, antigen-specific T-cell responses were not detected. In contrast, after a single intramuscular dose of Ad5-S or Ad41-S, functional antigen-specific T-cell responses were elicited in the spleen and pulmonary lymphocytes of the mice, which persisted for several months. Both rAd-based vaccines administered intramuscularly induced systemic humoral immune responses (neutralizing IgG antibodies). Our results show that a single dose of Ad5-S- or Ad41-S-based vaccines represents an appealing strategy for the control of MERS-CoV infection and transmission.
30
Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC
V. Stalin Raj, Huihui Mou, Saskia L. Smits et al. · Nature · 2013 · 2.1K citations · Full text
Evidence for Camel-to-Human Transmission of MERS Coronavirus
Esam I. Azhar, Sherif A. El‐Kafrawy, Suha A. Farraj et al. · New England Journal of Medicine · 2014 · 913 citations · Full text